SAN DIEGO, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. OBLN, a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its unaudited financial results as of and for the third quarter ended September 30, 2018.
Third Quarter 2018 highlights:
- Total revenue of $3.0 million increased 9% vs Q2-18
- US revenue of $1.8 million increased 17% vs Q2-18
- US Reorders were $1.4 million, or 79% of US sales, an increase of 45% vs Q2-18
- Gross margin of 53% increased from 37% in Q2-18
- Operating loss of $6.6 million improved 31% vs $9.6 million in Q2-18
- Net cash use of $5.5 million decreased 33% vs. use of $8.3 million in Q2-18
- Completed Private Placement raising gross proceeds of $10.0 million
- Received FDA PMA-S approval for the Obalon Touch Inflation System
- As part of a planned succession, on January 2, 2019 the Company will transition Kelly Huang, Ph.D. to the role of Chief Executive Officer and Andy Rasdal to the role of Chairman of the Board
The Company reported revenue of $3.0 million for the third quarter of 2018, compared to $2.7 million for the second quarter of 2018 and $2.8 million for the third quarter of 2017. Net loss was reported at $6.7 million for the third quarter of 2018, compared to $9.8 million for the second quarter of 2018 and $9.2 million for the third quarter of 2017. Net loss per share for the third quarter of 2018 was $0.35 as compared to $0.57 for the second quarter of 2018 and $0.55 for the third quarter of 2017.
Cost of revenue was $1.4 million for the third quarter of 2018, down from $1.7 million for the second quarter of 2018, and up from $1.3 million for third quarter of 2017. Gross profit for the third quarter of 2018 was $1.6 million, resulting in a gross margin of 53%, compared to a gross profit of $1.0 million and gross margin of 37% for the second quarter of 2018 and a gross profit of $1.5 million and gross margin of 53% for the third quarter of 2017.
Research and Development expense for the third quarter of 2018 totaled $2.4 million, down from $3.4 million for the second quarter of 2018 and $2.8 million for the third quarter of 2017. Selling, General and Administrative expense decreased to $5.8 million for the third quarter of 2018 as compared to $7.3 million for the second quarter of 2018 and $7.8 million for the third quarter of 2017.
Operating loss for the third quarter of 2018 was $6.6 million, down from $9.6 million for the second quarter of 2018 and $9.1 million for the third quarter of 2017.
As of September 30, 2018, cash, cash equivalents and short-term investments were $29.7 million.
Call Information
A conference call to discuss third quarter 2018 financial results is scheduled for today, November 2, 2018, at 8:30 AM Eastern Time (5:30 AM Pacific Time). Interested parties may access the conference call by dialing (844) 889-7791 (U.S.) or (661) 378-9934 (international) using passcode 6045357. Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event. The conference call will also be webcast live at: https://edge.media-server.com/m6/p/7sfacf89.
An archive of the webcast will be available for twelve months following the event on the Obalon Therapeutics, Inc. website located at http://investor.obalon.com/ in the "News & Events" section.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. OBLN is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit http://www.obalon.com/.
For Obalon Therapeutics, Inc.
Investor Contact:
William Plovanic
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
wplovanic@obalon.com
Media:
Megan Driscoll
EvolveMKD
Office Phone: +1 646 517 4220
mdriscoll@evolvemkd.com
OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except shares and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||
| (Unaudited) | |||||||||||||||
| Revenue | $ | 2,987 | $ | 2,787 | $ | 7,065 | $ | 6,222 | |||||||
| Cost of revenue | 1,418 | 1,314 | 3,919 | 3,127 | |||||||||||
| Gross profit | 1,569 | 1,473 | 3,146 | 3,095 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 2,368 | 2,798 | 8,359 | 7,958 | |||||||||||
| Selling, general and administrative | 5,836 | 7,813 | 23,092 | 19,606 | |||||||||||
| Total operating expenses | 8,204 | 10,611 | 31,451 | 27,564 | |||||||||||
| Loss from operations | (6,635 | ) | (9,138 | ) | (28,305 | ) | (24,469 | ) | |||||||
| Interest expense, net | (70 | ) | (21 | ) | (164 | ) | (110 | ) | |||||||
| Other expense | (40 | ) | (11 | ) | (155 | ) | (66 | ) | |||||||
| Net loss | (6,745 | ) | (9,170 | ) | (28,624 | ) | (24,645 | ) | |||||||
| Other comprehensive (loss) income | (3 | ) | 15 | 3 | (3 | ) | |||||||||
| Total comprehensive loss | $ | (6,748 | ) | $ | (9,155 | ) | $ | (28,621 | ) | $ | (24,648 | ) | |||
| Net loss per share, basic and diluted | $ | (0.35 | ) | $ | (0.55 | ) | $ | (1.60 | ) | $ | (1.48 | ) | |||
| Weighted-average common shares outstanding, basic and diluted | 19,457,971 | 16,747,791 | 17,837,297 | 16,649,447 | |||||||||||
OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except shares and par value data)
| September 30, 2018 | December 31, 2017 | ||||||
| Assets | (Unaudited) | ||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 21,552 | $ | 21,108 | |||
| Short-term investments | 8,116 | 23,292 | |||||
| Accounts receivable, net of allowance of $538 and $239, respectively | 2,775 | 4,223 | |||||
| Inventory | 1,955 | 1,418 | |||||
| Other current assets | 909 | 1,714 | |||||
| Total current assets | 35,307 | 51,755 | |||||
| Property and equipment, net | 1,572 | 1,346 | |||||
| Total assets | $ | 36,879 | $ | 53,101 | |||
| Liabilities and Stockholders' Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,458 | $ | 1,276 | |||
| Accrued compensation | 2,671 | 4,494 | |||||
| Deferred revenue | 301 | 510 | |||||
| Other current liabilities | 2,328 | 1,773 | |||||
| Current portion of long-term loan | 523 | 1,958 | |||||
| Total current liabilities | 7,281 | 10,011 | |||||
| Deferred rent | 46 | 13 | |||||
| Long-term loan, excluding current portion | 9,399 | 7,964 | |||||
| Total long-term liabilities | 9,445 | 7,977 | |||||
| Total liabilities | 16,726 | 17,988 | |||||
| Commitments and contingencies | |||||||
| Stockholders' equity: | |||||||
| Common stock, $0.001 par value; 100,000,000 and 300,000,000 shares authorized as of September 30, 2018 and December 31, 2017, respectively; 23,280,310 and 17,500,604 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively | 23 | 18 | |||||
| Additional paid-in capital | 160,130 | 146,474 | |||||
| Accumulated other comprehensive loss | (2 | ) | (5 | ) | |||
| Accumulated deficit | (139,998 | ) | (111,374 | ) | |||
| Total stockholders' equity | 20,153 | 35,113 | |||||
| Total liabilities and stockholders' equity | $ | 36,879 | $ | 53,101 | |||
OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Nine Months Ended September 30, | |||||||
| 2018 | 2017 | ||||||
| (Unaudited) | |||||||
| Operating activities: | |||||||
| Net loss | $ | (28,624 | ) | $ | (24,645 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Depreciation | 428 | 221 | |||||
| Stock-based compensation | 3,610 | 2,102 | |||||
| Fair value of stock issued for legal settlement | — | 1,398 | |||||
| Loss on disposal of fixed assets | 107 | — | |||||
| (Accretion) amortization of investment (discount) premium, net | (20 | ) | 24 | ||||
| Amortization of debt discount | 29 | 31 | |||||
| Change in operating assets and liabilities: | |||||||
| Accounts receivable, net | 1,448 | (2,515 | ) | ||||
| Accounts receivable from related party | — | 515 | |||||
| Inventory | (537 | ) | (84 | ) | |||
| Other current assets | 805 | 240 | |||||
| Accounts payable | 135 | 534 | |||||
| Accrued compensation | (1,823 | ) | 174 | ||||
| Deferred revenue | (209 | ) | 72 | ||||
| Other current and long term liabilities | 634 | 506 | |||||
| Net cash used in operating activities | (24,017 | ) | (21,427 | ) | |||
| Investing activities: | |||||||
| Purchases of short-term investments | (9,103 | ) | (80,317 | ) | |||
| Maturities of short-term investments | 24,302 | 41,500 | |||||
| Purchase of property and equipment | (867 | ) | (904 | ) | |||
| Net cash provided by (used in) investing activities | 14,332 | (39,721 | ) | ||||
| Financing activities: | |||||||
| Fees paid in connection with loan amendment | (30 | ) | — | ||||
| Proceeds from issuance of common stock, net of issuance costs | 9,973 | — | |||||
| Proceeds from stock issued under employee stock purchase plan | 148 | 210 | |||||
| Proceeds from sale of common stock upon exercise of stock options | 38 | 46 | |||||
| Net cash provided by financing activities | 10,129 | 256 | |||||
| Net increase (decrease) in cash and cash equivalents | 444 | (60,892 | ) | ||||
| Cash and cash equivalents at beginning of period | 21,108 | 72,975 | |||||
| Cash and cash equivalents at end of period | $ | 21,552 | $ | 12,083 | |||
| Supplemental cash flow information: | |||||||
| Interest paid | $ | 473 | $ | 416 | |||
| Unpaid issuance costs | $ | 160 | $ | — | |||
| Property and equipment in accounts payable | $ | 106 | $ | 126 | |||
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
